Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Executive Summary
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.
You may also be interested in...
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.